TITLE

BIOVAIL ACQUIRES MONOCOR MARKETING RIGHTS FOR CANADA

PUB. DATE
April 2000
SOURCE
Worldwide Biotech;Apr2000, Vol. 12 Issue 4, p3
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
Reports that Biovail Corp. has acquired under license the exclusive market and distribution rights in Canada for Monocor, a cardio-selective beta-blocker for treatment of hypertension.
ACCESSION #
3004622

 

Related Articles

  • NEW INDICATIONS.  // Drug Topics;6/2/2003, Vol. 147 Issue 11, p77 

    Reports on the approval of an indication for Coreg, a beta-adrenergic blocking agent from GlaxoSmithKline.

  • Effectiveness of preprinted order forms in promoting perioperative β-blocker use. Pollard, John B.; Chow, Rebecca C.; Hansen, Jeffrey R. // American Journal of Health-System Pharmacy;2/15/2002, Vol. 59 Issue 4, p359 

    Studies the effectiveness of preprinted order forms in promoting perioperative beta-blocker use. Study design and methods; Evidence that beta-blockers reduce morbidity and mortality rates in multiple settings; Benchmarking data for beta-blocker therapy in the perioperative period.

  • New beta blocker reduces heart failure mortality by two-thirds.  // Geriatrics;Jan96, Vol. 51 Issue 1, p16 

    Takes a look at the beta blocker/vasodilator carvedilo (Coreg) that reduces morality when given to patients with chronic heart failure who are already receiving the best proven therapy. Comments from Dr. Milton Packer MD; What was found in multicenter study.

  • Whoa! Propranolol for hand tremor.  // Patient Care;4/30/1997, Vol. 31 Issue 8, p56 

    Describes the efficacy of propranolol hydrochloride in the treatment of hand tremor. Propranolol-associated changes in the sample of the study; Effectiveness of beta-blockers in treating nervousness and tremor.

  • Beta-blocker developments aid glaucoma treatment. Prescott, Lawrence M. // Ophthalmology Times;10/01/97, Vol. 22 Issue 19, p79 

    Predicts the possible development and availability of even safer beta blockers for the treatment of glaucoma. Description of the characteristics of future drugs; Function of therapeutic index in the determination of the potency of the drugs; Background on the first attempts to improving beta...

  • Sympathetic overactivity in tetanus: fatality associated with propranolol. Buchanan, N.; Smit, L.; Cane, R.H.; de Andrade, M. // British Medical Journal;7/22/1978, Vol. 2 Issue 6132, p254 

    Examines the fatality associated with propranolol in the sympathetic overactivity in tetanus. Use of pharmacological agents to control the sympathetic crisis; Disadvantages in the use of beta-blockers in patients with tetanus; Complications in the use of propranolol.

  • Psoriasis as a side effect of Beta blockers. Savola, Jaakko; Vehvilainen, Outi; Vaatainen, Niilo J. // British Medical Journal (Clinical Research Edition);9/12/1987, Vol. 295 Issue 6599, p637 

    Analyzes the relation of psoriasis with beta blockers. Examination on the extent of psoriatic lesions in patients; Appearance of psoriatic lesions during beta blockade in patients; Conclusion on beta blockers.

  • Acebutolol--Induced Pleuropulmonary Lupus Syndrome. Record Jr., N. Burgess // Annals of Internal Medicine;Sep81, Vol. 95 Issue 3, p326 

    Presents a study on the effect of the beta-blocker acebutolol on pleuropulmonary lupus syndrome. Methodology; Results; Discussion.

  • Effects of Beta Blockade on the Peripheral Manifestations of Thyrotoxicosis. Grossman, William; Robin, Noel I.; Johnson, Lewis W.; Brooks, Harold; Selenkow, Herbert A.; Dexter, Lewis // Annals of Internal Medicine;Jun71, Vol. 74 Issue 6, p875 

    Deals with a study which aimed to determine the effects of beta adrenergic blockade with sotalol on the peripheral manifestations of thyrotoxicosis. Materials and methods used in the study; Results and discussion.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics